Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ali Darvishi, Ramin Abdi Dezfouli, Aliakbar Fazaeli, Rajabali Daroudi & Narges Zandieh. (2023) Is Palbociclib a cost-effective strategy in the second-line treatment of metastatic breast cancer in Iran?. Expert Review of Pharmacoeconomics & Outcomes Research 23:10, pages 1201-1210.
Read now
Read now
Mingjun Rui, Zhengyang Fei, Yingcheng Wang, Xueke Zhang, Aixia Ma, Haikui Sun & Hongchao Li. (2022) Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China. Journal of Medical Economics 25:1, pages 618-629.
Read now
Read now
Li-Jen Cheng, Lydia Loke, Elaine Hsuen Lim, Fiona Pearce, Mohamed Ismail Abdul Aziz & Kwong Ng. (2021) Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore. Expert Review of Pharmacoeconomics & Outcomes Research 21:3, pages 449-456.
Read now
Read now
Patrick Neven, Gabe S Sonke & Guy Jerusalem. (2021) Ribociclib plus fulvestrant in the treatment of breast cancer. Expert Review of Anticancer Therapy 21:1, pages 93-106.
Read now
Read now
Articles from other publishers (16)
Prajakta P. Masurkar, Haluk Damgacioglu, Ashish A. Deshmukh & Meghana V. Trivedi. (2023) Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA. PharmacoEconomics 41:6, pages 709-718.
Crossref
Crossref
Nour Hisham Al-Ziftawi, Mohammed Fasihul Alam, Shereen Elazzazy, Asrul Akmal Shafie, Anas Hamad & Mohamed Izham Mohamed Ibrahim. (2022) Cost-Effectiveness and Cost-Utility of Palbociclib versus Ribociclib in Women with Stage IV Breast Cancer: A Real-World Data Evaluation. International Journal of Environmental Research and Public Health 20:1, pages 512.
Crossref
Crossref
Aline Silveira Silva, Ana Cláudia Wekmuller França, Matheus Piccin Padilla, Luana Schroeder Macedo, Carlos Alberto da Silva Magliano & Marisa da Silva Santos. (2022) Brazilian breast cancer patient-reported outcomes: What really matters for these women. Frontiers in Medical Technology 4.
Crossref
Crossref
Luana Schroeder Damico Nascimento Macedo, Aline Silveira Silva, Ana Cláudia Wekmuller França, Carlos Alberto da Silva Magliano, Isandra Meirelles, Matheus Piccin Padilla & Marisa da Silva Santos. (2022) Cost-Utility of the CDK 4/6 Inhibitors for Postmenopausal Women With Luminal Advanced Breast Cancer in Brazil. Value in Health Regional Issues 31, pages 47-52.
Crossref
Crossref
Pingyu Chen, Xintian Wang, Shengwen Zhu, Hongchao Li, Mingjun Rui, Yingcheng Wang, Haikui Sun & Aixia Ma. (2022) Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC. Frontiers in Public Health 10.
Crossref
Crossref
Wedad H. Alotaibi, Majd M. Alhamdan & Bander Balkhi. (2022) Cost-effectiveness of Ribociclib in HER2- negative breast cancer: A synthesis of current evidence. Saudi Pharmaceutical Journal 30:8, pages 1113-1119.
Crossref
Crossref
Nidhi Gupta, Dharna Gupta, Jyoti Dixit, Nikita Mehra, Ashish Singh, Manjunath Nookala Krishnamurthy, Gaurav Jyani, Kavitha Rajsekhar, Jayachandran Perumal Kalaiyarasi, Partha Sarathi Roy, Prabhat Singh Malik, Anisha Mathew, Pankaj Malhotra, Sudeep Gupta, Lalit Kumar, Amal Kataki & Shankar Prinja. (2022) Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women. Applied Health Economics and Health Policy 20:4, pages 609-621.
Crossref
Crossref
Yingcheng Wang, Mingjun Rui, Xin Guan, Yingdan Cao & Pingyu Chen. (2021) Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective. Frontiers in Medicine 8.
Crossref
Crossref
Lydia Loke, Soo‐Chin Lee, Fiona Pearce, Kwong Ng & Mohamed Ismail Abdul Aziz. (2020) Cost‐effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore. Cancer Reports 4:1.
Crossref
Crossref
Anna Maria Buehler, Gabriela Castilho, Pierre-Alexandre Dionne & Stephen Stefani. (2021)
Cost-effectiveness of ribociclib plus letrozole
versus
palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective
. Therapeutic Advances in Medical Oncology 13, pages 175883592110005.
Crossref
Crossref
Thomas Decker, Robert Seifert, Matthias Bichler, Andrea Birtel, Gerhard Fischer, Christoph Nonnenbroich & Tobias Dechow. (2021) Elective Discontinuation of CDK4/6 Inhibitors in Patients with Metastatic Hormone Receptor-Positive, Her-2-Negative Breast Cancer: A Retrospective Single-Center Experience. Oncology Research and Treatment 44:9, pages 443-449.
Crossref
Crossref
Lee Cheng Phua, Soo Chin Lee, Kwong Ng & Mohamed Ismail Abdul Aziz. (2020) Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer. BMC Health Services Research 20:1.
Crossref
Crossref
Aram BabcockAskal Ayalew AliRajesh BalkrishnanAlberto MonteroVakaramoko Diaby. (2020) Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER2 Negative Metastatic Breast Cancer: A Commentary. Journal of Managed Care & Specialty Pharmacy 26:7, pages 826-831.
Crossref
Crossref
Jinani Jayasekera & Jeanne S. Mandelblatt. (2020) Systematic Review of the Cost Effectiveness of Breast Cancer Prevention, Screening, and Treatment Interventions. Journal of Clinical Oncology 38:4, pages 332-350.
Crossref
Crossref
Robert J Cersosimo. (2019) Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women. American Journal of Health-System Pharmacy 76:16, pages 1183-1202.
Crossref
Crossref
. (2018) Ribociclib cost effective for HR+/HER2− advanced breast cancer. PharmacoEconomics & Outcomes News 817:1, pages 29-29.
Crossref
Crossref